BioCentury
ARTICLE | Clinical News

Trabedersen: Phase III started

May 4, 2009 7:00 AM UTC

Antisense began the open-label, active-controlled, international Phase III SAPPHIRE trial to compare 10 µM of intratumoral trabedersen given every other week vs. standard chemotherapy with temozolomid...